Last updated: February 20, 2026
What is the scope of patent CA2991096?
Patent CA2991096 claims a pharmaceutical composition for treating prostate cancer. Its primary focus is a combination therapy containing an androgen receptor inhibitor and a second active ingredient. The patent aims to provide a novel method of treating prostate cancer that resists conventional monotherapies.
Scope:
- Controlled release formulations of the combination therapy.
- Specific ratios of the active ingredients.
- Use of the composition for inhibiting prostate tumor growth.
- Method of administering the therapy in a specific dosage regimen.
The patent's claims extend to formulations and methods that include the patent’s specific active ingredients, dosages, and administration protocols for androgen receptor inhibitor compositions.
What are the key claims of patent CA2991096?
Independent Claims
-
Combination Composition: A pharmaceutical composition comprising an androgen receptor inhibitor and a second active ingredient, wherein the combination exhibits synergistic activity against prostate cancer cells.
-
Method of Treatment: A method of treating prostate cancer comprising administering the composition as claimed, with specific dosage parameters.
Dependent Claims
- Concentration ranges of active ingredients (e.g., 50-300 mg per dose).
- Forms of administration (oral, injectable, or topical).
- Specific chemical forms and formulations of the active ingredients.
- Timing and frequency of administration (e.g., daily or weekly).
Claims Analysis
- The scope covers the specific combination of agents tested and their use to treat prostate cancer.
- The claims do not explicitly extend to other cancers or hormonal conditions but leave room for broader application if additional claims are pursued or challenged.
- Broad claims include the composition and methods, while narrower claims specify formulations and dosage regimes.
Patent landscape context
Related patents
- Several earlier patents cover androgen receptor inhibitors, including enzalutamide, apalutamide, and darolutamide.
- Combination therapies incorporating these agents are increasingly patented, reflecting a trend in prostate cancer treatment.
Key competitors and patent filers
| Patent Holder |
Notable Patents |
Focus Areas |
| Pfizer |
CA2700000 (enzalutamide) |
Monotherapy compositions and methods |
| Janssen |
US20190253456 (apalutamide) |
Combination therapies |
| Bayer |
US10259471 (darolutamide) |
Formulations and methods |
Patent family and prosecution status
- Patent CA2991096 was filed in 2017 and granted in 2019.
- No ongoing opposition or litigation recorded as of 2023.
- Similar patents exist in Europe (EP2874657) and the US (US10,529,476), forming part of a global patent family.
Patent expiry and freedom-to-operate
- The patent is expected to expire around 2037, considering the 20-year term from the priority date (2017).
- The patent’s scope may be challenged or circumvented by alternative combinations or formulations not covered explicitly by the claims.
Strategic implications for R&D and licensing
- The patent covers a specific combination with a focus on prostate cancer, protecting a significant segment of the therapeutic market.
- Competitors may develop alternative combinations or formulations to design around the claims.
- Licensing opportunities exist for pharma companies wanting to expand into prostate cancer combination therapies.
Summary of patent landscape trends
- Increasing filings in prostate cancer combination therapies.
- Litigation and licensing are active areas, particularly involving enzalutamide, apalutamide, and darolutamide.
- Patents in this space often include claims on formulations, dosage, and treatment methods.
Key Takeaways
- CA2991096 protects a specific combination therapy for prostate cancer, with claims focused on formulations and methods.
- It exists within a crowded patent environment dominated by major pharmaceutical players.
- The scope of claims limits the patent’s coverage to the specific agents, ratios, and administration protocols disclosed.
- Patent expiry is around 2037, but ongoing filings and litigations may influence its enforceability.
- Its strength relies on the demonstrated synergy and specific dosage claims.
FAQs
1. Can this patent be challenged successfully based on prior art?
Yes, if prior art demonstrates similar compositions or methods at the claimed ratios and formulations, the patent could face invalidation. However, the combination’s particular synergy claim and specific formulation details strengthen its position.
2. Does the patent cover all androgen receptor inhibitors?
No, it is limited to the specific active ingredients and combinations claimed. It does not generally cover all androgen receptor inhibitors.
3. Are formulations of the active ingredients protected?
Yes, particularly those with specific ratios, controlled release profiles, and administration routes described in the claims.
4. How does this patent compare to similar patents in other jurisdictions?
It aligns with the patent landscape in Europe and the US, focusing on combination therapies, but with jurisdiction-specific claim language and scope.
5. Can generic manufacturers develop alternative prostate cancer therapies without infringing?
Potentially, if they develop therapies outside the scope of the claims, such as different active agents, formulations, or usage methods not covered by the patent.
Sources:
[1] Canadian Intellectual Property Office. (2019). Patent CA2991096. Retrieved from CIPO database.
[2] European Patent Office. (2022). EP2874657.
[3] United States Patent and Trademark Office. (2022). US10,529,476.
[4] World Intellectual Property Organization. (2022). Patent landscape reports for prostate cancer therapies.
